AtaiBeckley (ATAI) EBITDA Margin (2021 - 2026)
AtaiBeckley's (ATAI) quarterly EBITDA Margin came in at 3239.1% in Q1 2026, down 192913.0% year-on-year from N/an in Q1 2025, and down 147.27% quarter-over-quarter from 1309.97% in Q1 2025.
AtaiBeckley (ATAI) EBITDA Margin (2021 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 5 years of EBITDA Margin data on file, last reported at 3796.53% in Q3 2025.
- For the quarter ending Q3 2025, EBITDA Margin rose 5270847.0% year-over-year to 3796.53%; the trailing twelve-month figure through Sep 2025 stood at 3438.02% (up 2857920.0% YoY), and the FY2024 full-year result was 33341.23%, up 661768.0% from the prior year.
- EBITDA Margin slipped to 3239.1% in Q1 2026 per ATAI's latest filing, from 1309.97% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1309.97% in Q1 2025 and bottomed at 3239.1% in Q1 2026.
- A 5-year average of 60266.07% and a median of 20219.77% in 2021 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin tumbled 14755410 bps in 2022 and soared 12925216 bps in 2023, its largest moves.
- Tracing ATAI's EBITDA Margin over 5 years: stood at 19641.3% in 2021, then plunged by 403 bps to 98855.26% in 2022, then slumped by 89 bps to 186450.0% in 2023, then plunged by 35 bps to 252208.33% in 2024, then surged by 98 bps to 3796.53% in 2025.
- Business Quant data shows ATAI's EBITDA Margin at 3796.53% in Q3 2025, 3515.02% in Q2 2025, and 1309.97% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - | -3,796.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,239.10% |
| Sep 30, 2025 | -3,796.53% |
| Jun 30, 2025 | -3,515.02% |
| Mar 31, 2025 | -1,309.97% |
| Mar 31, 2025 | -1,309.97% |
| Dec 31, 2024 | -252,208.33% |
| Sep 30, 2024 | -56,505.00% |
| Jun 30, 2024 | -9,424.54% |
| Dec 31, 2023 | -186,450.00% |
| Sep 30, 2023 | -30,843.68% |
| Jun 30, 2023 | -18,524.42% |
| Mar 31, 2023 | -89,767.57% |
| Dec 31, 2022 | -98,855.26% |
| Sep 30, 2022 | -160,095.83% |
| Jun 30, 2022 | -20,798.24% |
| Dec 31, 2021 | -19,641.30% |
| Sep 30, 2021 | -12,541.73% |
| Mar 31, 2021 | 20.37% |